Clinical Trial

Clinical Trial Epygenix is doing a A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 as Adjunctive Therapy in Patients with Dravet Syndrome. Detailed information for inclusion and exclusion criteria are available at...

Therapeutic Focus

Therapeutic Focus Our initial focus is on Dravet Syndrome (DS), a catastrophic childhood epilepsy. As a group catastrophic childhood epilepsies are characterized by debilitating developmental or cognitive co-morbidities, and seizures in these children are poorly...